ArticleCureus2025
Atypical Autoimmune Encephalitis: Diagnostic Challenges and Therapeutic Insights From a Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Encephalitis syndromes are acute neurological emergencies characterized by altered sensorium, seizures, movement disorders, and neuropsychiatric manifestations. Autoimmune encephalitis (AE), although rare, necessitates prompt recognition and intervention to reduce morbidity and mortality. This study aimed to examine the clinical features, laboratory findings, radiological characteristics, and treatment outcomes of patients diagnosed with autoimmune encephalitis. This case series presents six patients diagnosed with autoimmune encephalitis and admitted to the Department of General Medicine at the All India Institute of Medical Sciences (AIIMS), Mangalagiri, between January 2024 and January 2025. The mean age of onset was 30.4 years. The cohort included two cases of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis, one case with both myelin oligodendrocyte glycoprotein (MOG) and anti-NMDA receptor antibodies, one case of seronegative autoimmune encephalitis (SNAE) diagnosed based on magnetic resonance imaging (MRI) findings, one case of Rasmussen's encephalitis (RE), and one case of paraneoplastic autoimmune encephalitis (PAE) associated with lung malignancy. This study provides a comprehensive overview of clinical presentations, treatment approaches, and patient outcomes. Early diagnosis and timely initiation of immunosuppressive therapy are crucial for improving patient outcomes. Diagnosis relies on clinical assessment, neuroimaging, and antibody testing, with seronegative cases requiring a high degree of clinical suspicion for appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.